Radioimmunoscintigraphy in patients with breast adenocarcinoma using technetium-99m labelled monoclonal antibody 170H.82: report of a phase II study.

MLA

McQuarrie, S. A., et al. “Radioimmunoscintigraphy in Patients with Breast Adenocarcinoma Using Technetium-99m Labelled Monoclonal Antibody 170H.82: Report of a Phase II Study.” European Journal of Nuclear Medicine, vol. 24, no. 4, Apr. 1997, pp. 381–89. EBSCOhost, https://doi.org/10.1007/BF00881809.

APA

McQuarrie, S. A., MacLean, G. D., Boniface, G. R., Golberg, K., & McEwan, A. J. (1997). Radioimmunoscintigraphy in patients with breast adenocarcinoma using technetium-99m labelled monoclonal antibody 170H.82: report of a phase II study. European Journal of Nuclear Medicine, 24(4), 381–389. https://doi.org/10.1007/BF00881809

Chicago

McQuarrie, S A, G D MacLean, G R Boniface, K Golberg, and A J McEwan. 1997. “Radioimmunoscintigraphy in Patients with Breast Adenocarcinoma Using Technetium-99m Labelled Monoclonal Antibody 170H.82: Report of a Phase II Study.” European Journal of Nuclear Medicine 24 (4): 381–89. doi:10.1007/BF00881809.